A zebrafish model for VHL and hypoxia signaling

Area of Science:

• Genetics
• Molecular Biology
• Oncology

Background:

• The von Hippel-Lindau (VHL) gene encodes a tumor suppressor protein (pVHL) regulating critical cellular functions.
• Mutations in VHL lead to VHL disease, congenital polycythemia, and various sporadic tumors.
• Recent research has expanded understanding of pVHL's cellular roles and VHL-associated disease phenotypes.

Purpose of the Study:

• To review current knowledge on VHL gene function and associated diseases.
• To highlight the utility of animal models, particularly zebrafish, for studying VHL disease.
• To explore the potential of zebrafish models for identifying therapeutic targets and biomarkers.

Main Methods:

• Review of fundamental and clinical research on VHL disease over the past 15 years.
• Analysis of existing literature on VHL gene function and animal models.
• Focus on zebrafish VHL mutants as a model system for VHL disease.

Main Results:

• Zebrafish vhl mutants recapitulate key human VHL disease features, including HIF pathway activation, polycythemia, neovascularization, macular edema, and pronephric abnormalities.
• The zebrafish model provides a platform for identifying genetic pathways and modifiers involved in VHL-associated tumors.
• VHL mutants in zebrafish are valuable for studying genotype-phenotype correlations and discovering prognostic biomarkers.

Conclusions:

• Zebrafish serve as a clinically relevant in vivo model for VHL disease research.
• The zebrafish model facilitates the identification of novel therapeutic agents and regulatory processes involving VHL.
• Further research using zebrafish can advance our understanding of VHL-associated neoplasms and guide therapeutic strategies.